DOCSLIB.ORG

Medicine Directory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicine Directory Medicine Directory The purpose of the Trust Medicine Directory is to assist clinicians with evidence based, clinical and cost effective advice and information when prescribing medication for the management of mental health and behavioural conditions and medication associated side effects. For medication prescribed for the management of physical health conditions refer to local joint formulary recommendations (this also applies to medication included in this list when prescribed for physical health condition, e.g. prochlorperazine for nausea and vomiting or valproate for epilepsy). The aims of the Trust Medicine Directory are to: Promote adherence to existing prescribing guidance and advice (national and local) Raise awareness of and signpost clinicians to relevant prescribing guidelines, protocols and safety alerts to enable the safe and effective use of medicines. Ensure clinicians are aware of current information and advice in order to maximise the potential for individuals, teams and services to achieve Trust agreed cost improvement plans for prescribing. Raise awareness to specific resources and tools available to healthcare professionals which can be used to help support optimal prescribing and treatment with medication through shared decision making. The Medicine Directory is not intended to replace prescribing information contained in the BNF and / or Summary of Product Characteristics for specific medications, nor is it intended to replace advice included in locally developed joint formularies (which are inclusive of all conditions and not just mental health) The Medicine Directory is arranged in alphabetical order of medication with a list of conditions for which the medication may be prescribed. The following key is used to indicate the current status for each medication which is condition specific (i.e. evidence may support use for the management of depression but not anxiety). No approval required. Prescribe in accordance with Trust recommendations NON-APPROVED MEDICATION Approval is required by your Clinical Director or Associate Clinical Director prior to prescribing in order to agree that the medication is clinically appropriate, and to accept the impact on the prescribing budget. These medicines may be: Medicines that are not commissioned by the CCG Medicines that are commissioned but with conditional measures based on adherence to locally agreed procedures Please refer to Standard Operating Procedure MM26 and complete a Non-Approved Medication form (click here to access the SOP and form) These medicines are not recommended due to: Concerns over safety or effectiveness Insufficient evidence Cost effectiveness (more expensive compared to equivalent treatment options) Record the clinical rationale for treatment in the electronic patient record and discuss the treatment with your local pharmacist and/or peers. If prescribing is to continue, please refer to Standard Operating Procedure MM26 and complete a Non-Approved Medication form (click here to access the SOP and form) Refer to local joint formulary Medicine Directory Devon Partnership Trust - Drugs and Therapeutics Committee Version 18.0 – Feb 19 Page 1 of 22 Prescribing Off-Licence and Unlicensed Medicines Clinicians should always prescribe licensed medicines for licensed indications in preference to the ‘off-licence’ use of medicines (which includes indication, dose and method of administration) or unlicensed medicines. However, the Trust recognizes that prescribing of ‘off-licence’ (‘off-label’) or unlicensed medication, is occasionally necessary in order to offer and provide the optimum treatment for an individual, and in these circumstances Trust Standard Operating Procedure MM06 ‘Prescribing Unlicensed and Off- Label Medication’ must be adhered to. Trust categorisation of ‘off-label’ and ‘unlicensed prescribing’ is summarised below; Level 1 'Off-label' prescribing of a licensed drug where use is recognised in prescribing guidelines (L1) issued by The National Institute for Health and Care Excellence (NICE) and / or robust evidence of efficacy is available and reflected in the Trust Medicine Directory Level 2 'Off-label' prescribing of a licensed drug where supporting evidence is weak. (L2) Off-label indication for medication not included in Trust Medicine Directory (unless highlighting that prescribing is not recommended due to lack of evidence to support efficacy and / or safety profile) As of December 2017 it is recommended that clinicians seek a second opinion using the non-approved medicines process when prescribing level 2 off label items Level 3 Prescribing of an Unlicensed drug (Medication without UK Marketing authorisation or (L3) Central European Licence) As of December 2017 it is recommended that clinicians seek a second opinion using the non-approved medicines process when prescribing level 3 unlicensed medicines Keeping the Medicine Directory Up To Date The Medication Directory will be reviewed and updated by the Trust Drugs and Therapeutics Committee (DTC) on a monthly basis. This will be completed in collaboration with Medicine Optimisation Teams and Formulary Interface Groups (FIGs) within the local Clinical Commissioning Groups (CCGs). Please contact the Medicines Optimisation Team if you would like further information about this process. New Medications The definition of a ‘new drug’ is a newly launched treatment or a ‘new indication and / or formulation’ of an existing treatment. At the time of launch, new medicines will be included in the Medicine Directory as ‘Non-approved drugs’ and the stage of evaluation stated (i.e. “Awaiting commissioning decision from CCG Clinical Policy Committee”). Following a commissioning decision the non-approved status will be updated to reflect this. Generic and Brand Prescribing Prescribing medicines generically rather than by brand name can improve cost-effectiveness and is encouraged. However, there are some circumstances in which brand-name prescribing is preferred in order to support the safe and clinically effective delivery of treatment with medication. These include: Where there is a difference in bioavailability between brands of the same medicine, particularly if the medicine has a narrow therapeutic index Where modified release preparations are not interchangeable Where there are important differences in formulation between brands of the same medicine Where products contain multiple ingredients and brand name prescribing aids identification Where administration devices (e.g. inhaler or self-injection) have different instructions for use and patient familiarity with the same product is important Where different preparations of the same medicine have different licensed indications Medicine Directory Devon Partnership Trust - Drugs and Therapeutics Committee Version 18.0 – Feb 19 Page 2 of 22 Even where there is only one brand available, products should still be prescribed generically unless one of the reasons listed above applies. The reason for this is so that if / when a generic version becomes available, prescribing practice will not have to change and financial savings from generic prescribing will be maximised. Occasionally there will be a requirement to prescribe a branded generic version of a medicine to realise financial savings. The following symbol in the Medicine Directory indicates that medication should be prescribed by brand in order to support treatment efficacy and / or patient safety. Research and Development The Trust’s overarching research and development aims are to maximise the participation of people using its services in clinical research, innovation and improvement projects by increasing the Trust’s participation in the National Institute for Health Research portfolio studies which are open to recruitment, other high quality research and clinical trials. In order to raise awareness, where the organisation is actively involved in a research project that involves prescribing medication, information will be included in the Directory. Clinicians should contact the Research and Development Department or the Primary Investigator for more information. Cost Improvement Plans The Medicines Optimisation Team proactively works with prescribers and teams to minimize the routine costs associated with prescribing on a daily basis without compromising the safety and efficacy of treatment. Advice on optimising prescribed medication and minimising associated costs is included in the Directory under individual drugs where applicable. Cost Comparison Charts for the most commonly used medications are available here Further information and advice about safe and effective prescribing can be obtained by: Visiting the Trust Medicines Optimisation Team’s intranet site: http://daisy.exe.nhs.uk/quality-safety/medicines-optimisation.aspx Visiting the Devon Partnership Trust’s internet site for prescribers and professionals: http://www.devonpartnership.nhs.uk/For-prescribers-and-professionals.513.0.html Telephoning or emailing the Trust Medicines Optimisation Team: – Direct Dial 01392 675674 – Email address [email protected] Calling the Trust Medicines Helpline (for staff and people who use our services) Visiting the Choice and Medication Website (For staff and people who use our services) If any supporting document links do not work, please inform the Medicines Optimisation Team: [email protected] Medicine Directory Devon Partnership Trust - Drugs and Therapeutics Committee Version 18.0 – Feb 19 Page 3 of 22 Prescribing Support Documents MEDICATION Indication
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia Thomas J
    In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia Thomas J. Raedler, M.D., Michael B. Knable, D.O., Douglas W. Jones, Ph.D., Todd Lafargue, M.D., Richard A. Urbina, B.A., Michael F. Egan, M.D., David Pickar, M.D. , and Daniel R. Weinberger, M.D. Olanzapine is an atypical antipsychotic with potent than low-dose in the same regions. Muscarinic occupancy ϭ antimuscarinic properties in vitro (Ki 2–25 nM). We by olanzapine ranged from 13% to 57% at 5 mg/dy and studied in vivo muscarinic receptor occupancy by 26% to 79% at 20 mg/dy with an anatomical pattern olanzapine at both low dose (5 mg/dy) and high dose (20 indicating M2 subtype selectivity. The [I-123]IQNB data mg/dy) in several regions of cortex, striatum, thalamus and indicate that olanzapine is a potent and subtype-selective pons by analyzing [I-123]IQNB SPECT images of seven muscarinic antagonist in vivo, perhaps explaining its low schizophrenia patients. Both low-dose and high-dose extrapyramidal side effect profile and low incidence of olanzapine studies revealed significantly lower anticholinergic side effects. [Neuropsychopharmacology [I-123]IQNB binding than that of drug-free schizophrenia 23:56–68, 2000] Published by Elsevier Science Inc. on patients (N ϭ 12) in all regions except striatum. behalf of the American College of Neuropsychopharmacology [I-123]IQNB binding was significantly lower at high-dose KEY WORDS: Muscarinic receptor; Olanzapine; IQNB; cologically (Watling et al. 1995) and correspond to SPECT; Schizophrenia; Antipsychotic genes (respectively, m1–m5) that have been cloned (Bonner et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed Et Al
    US0078.93053B2 (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed et al. (45) Date of Patent: Feb. 22, 2011 (54) TREATING PSYCHOLOGICAL CONDITIONS WO WO 2006/127418 11, 2006 USING MUSCARINIC RECEPTORM ANTAGONSTS (75) Inventors: Brian Seed, Boston, MA (US); Jordan OTHER PUBLICATIONS Mechanic, Sunnyvale, CA (US) Chau et al. (Nucleus accumbens muscarinic receptors in the control of behavioral depression : Antidepressant-like effects of local M1 (73) Assignee: Theracos, Inc., Sunnyvale, CA (US) antagonist in the porSolt Swim test Neuroscience vol. 104, No. 3, pp. 791-798, 2001).* (*) Notice: Subject to any disclaimer, the term of this Lind et al. (Muscarinic acetylcholine receptor antagonists inhibit patent is extended or adjusted under 35 chick Scleral chondrocytes Investigative Ophthalmology & Visual U.S.C. 154(b) by 726 days. Science, vol.39, 2217-2231.* Chau D., et al., “Nucleus Accumbens Muscarinic Receptors in the (21) Appl. No.: 11/763,145 Control of Behavioral Depression: Antidepressant-like Effects of Local M1 Antagonists in the Porsolt Swin Test.” Neuroscience, vol. (22) Filed: Jun. 14, 2007 104, No. 3, Jun. 14, 2001, pp. 791-798. Bechtel, W.D., et al., “Biochemical pharmacology of pirenzepine. (65) Prior Publication Data Similarities with tricyclic antidepressants in antimuscarinic effects only.” Arzneimittelforschung, vol. 36(5), pp. 793-796 (May 1986). US 2007/O293480 A1 Dec. 20, 2007 Chau, D.T. et al., “Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local Related U.S. Application Data Mantagonist in the Porsolt Swim test.” Neuroscience, vol. 104(3), (60) Provisional application No.
    [Show full text]
  • There Is More to Healing Ulcers Than Suppressing Acid
    Gut, 1986, 27, 475-480 Gut: first published as 10.1136/gut.27.5.475 on 1 May 1986. Downloaded from Leading article There is more to healing ulcers than suppressing acid The finding that a given acid output might be associated with a normal stomach, or with an ulcer, has stimulated only modest interest in factors such as pepsin and the mucosal barrier, as recently discussed in these columns by Mr Venables.' This is because it is difficult to make objective measurements, (especially in man) of the mucosal barrier2 and even of pepsin.3 The mucosal barrier is a theoretical concept dealing with the ability of the mucosa to resist digestion by acid and pepsin. There are many factors involved in preserving an intact epithelium: mucus and its adherence to the epithelium, bicarbonate secretion deep to the mucus, epithelial cellular integrity, hydrophobicity, mucosal blood flow and interstitial bicarbonate. These factors have been extensively reviewed by several authors,2 5-7 and so will not be discussed further. Pepsin is also important but comprises several proteolytic enzymes which have slightly different characteristics such as varying pH for optimal activity,8 with a predominance of pepsin I secretion in duodenal ulceration. Pepsin secretion is substantially increased in duodenal ulcer patients.9 In patients whose ulcers do not heal with cimetidine there is not only poor http://gut.bmj.com/ suppression of acid secretion, but an even smaller reduction in pepsin output. 10 On the other hand attempts to correlate pepsin with ulcer activity and individual response to cimetidine have been disappointing"l and inhibition of peptic activity by amylopectin sulphate has not proved advantageous in healing duodenal ulcers.'2 Against this uncertain background Baron et al, have investigated the on October 1, 2021 by guest.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • A Method to Determine the Ability of Drugs to Diffuse Through the Blood-Brain Barrier ANNA SEELIG*T, RUDOLF GOTTSCHLICHI, and RALF M
    Proc. Natl. Acad. Sci. USA Vol. 91, pp. 68-72, January 1994 Pharmacology A method to determine the ability of drugs to diffuse through the blood-brain barrier ANNA SEELIG*t, RUDOLF GOTTSCHLICHI, AND RALF M. DEVANTf *Biocenter of the University of Basel, Klingelbergstrasse 70, 4056 Basel, Switzerland; and tMedicinal Chemistry Research Laboratories, CNS Department, E. Merck, Frankfurter Strasse 250, 6100 Darmstadt, Germany Communicated by Harden M. McConnell, September 13, 1993 ABSTRACT A method has been devised for predicting the groups, (ii) the number of charged groups and their extent of ability of drugs to cross the blood-brain barrier. The criteria ionization, and (iii) the molecular size. Interestingly, the depend on the amphiphilic properties of a drug as reflected in same three parameters also determine the surface activity Its surface activity. The assessment was made with various and their combined action can be evaluated in a single drugs that either penetrate or do not penetrate the blood-brain experiment by measuring the Gibbs adsorption isotherm. barrier. The surface activity of these drugs was quantified by Here the chromatographically determined lipophilicity their Gibbs adsorption isotherms in terms ofthree parameters: constants are compared with measurements of the surface (i) the onset of surface activity, (ii) the critical micelle concen- activity for a large number of structurally different com- tration, and (iii) the surface area requirement ofthe drug at the pounds known to cross or not to cross the BBB. The air/water interface. A calibration diagram is proposed in predictive value of the surface activity measurements as a which the critical miceUe concentration is plotted against the function of concentration is distinctly higher than that of the concentration required for the onset of surface activity.
    [Show full text]
  • 5-Hydroxytryptamine Andhuman Small Intestinal Motility
    496 Gut 1994; 35:496-500 5-Hydroxytryptamine and human small intestinal motility: effect ofinhibiting 5-hydroxytryptamine reuptake D A Gorard, G W Libby, M J G Farthing Abstract nature is poorly understood.'0 In animals, Parenteral 5-hydroxytryptamine stimulates migrating motor complex cycling can be small intestinal motility, but the effect of con- modified by administration of 5-HT, its pre- tinuous stimulation with 5-hydroxytryptamine cursor 5-hydroxytryptophan, and its antago- on the human migrating motor complex is nists." '4 The effect of 5-HT on the migrating unknown. Using a selective 5-hydroxytrypta- motor complex in humans has not been studied. mine reuptake inhibitor, paroxetine, this study Tachyphylaxis to 5-HT given intravenously,45 investigated the effect of indirect 5-hydroxy- and associated cardiovascular and pulmonary tryptamine agonism on fasting small responses limit prolonged infusion of 5-HT in intestinal motility and transit. Eight healthy humans. The effect, however, of 5-HT agonism subjects were studied while receiving paroxe- on human small intestinal motor function might tine 30 mg daily for five days and while receiv- be alternatively investigated using a selective ing no treatment, in random order. Ambulant 5-HT reuptake inhibitor. Paroxetine selectively small intestinal motility was recorded from five inhibits the neuronal reuptake of 5-HT, increas- sensors positioned from the duodenojejunal ing the availability of synaptic 5-HT. Its ability flexure to the ileum for 16-18 hours. Paroxe- to inhibit 5-HT reuptake exceeds its ability to tine reduced the migrating motor complex inhibit noradrenaline reuptake by a factor of periodicity mean (SEM) from 81 (6) min to 67 320," making it four to five hundred times (4) min (p<005), and increased the propaga- as selective as the standard tricycic anti- tion velocity of phase III from 3-1 to 4-7 cm/ depressants imipramine and amitriptyline.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Appendix 1 BNF Codes of Drugs Lists Used to Define Exposure Groups
    Appendix 1 BNF Codes of drugs lists used to define exposure groups. Anticholinergic antipsychotics d411. Chlorpromazine d412. Chlorpromazine d413. Chlorpromazine d414. Chlorpromazine d415. Chlorpromazine d41a. Chlorpromazine d41b. Chlorpromazine d41c. Chlorpromazine d41d. Chlorpromazine d4b1. Perphenazine d4e1. PROMAZINE d4ex. PROMAZINE d4g.. Thioridazine d4g1. Thioridazine d4g2. Thioridazine d4g3. Thioridazine d4g5. Thioridazine d4g7. Thioridazine d4gp. Thioridazine d4gt. Thioridazine d4gu. Thioridazine d4gv. Thioridazine d4gw. Thioridazine d4gz. Thioridazine d4h.. Trifluoperazine d4h1. Trifluoperazine d4h2. Trifluoperazine d4h3. Trifluoperazine d4h4. Trifluoperazine d4hs. Trifluoperazine d4ht. Trifluoperazine d4hu. Trifluoperazine d4hx. Trifluoperazine d4l2. CLOZAPINE d4r1. OLANZAPINE d4r3. OLANZAPINE d4r7. OLANZAPINE d4s1. QUETIAPINE d4s2. QUETIAPINE d4s3. QUETIAPINE d4s5. QUETIAPINE d4ss. QUETIAPINE d4sx. QUETIAPINE Tricyclic antidepressants d7... d71.. Amitriptyline d711. Amitriptyline d712. Amitriptyline d713. Amitriptyline d719. Amitriptyline d71a. Amitriptyline d71b. Amitriptyline d71c. Amitriptyline d71d. Amitriptyline d71e. Amitriptyline d71f. Amitriptyline d71u. Amitriptyline d71v. Amitriptyline d71w. Amitriptyline d71y. Amitriptyline d71z. Amitriptyline d73.. Clomipramine d731. Clomipramine d732. Clomipramine d733. Clomipramine d736. Clomipramine d73s. Clomipramine d73t. Clomipramine d73u. Clomipramine d73v. Clomipramine d73w. Clomipramine d73z. Clomipramine d75.. DOSULEPIN d751. DOSULEPIN d752. DOSULEPIN d755. DOSULEPIN d756.
    [Show full text]
  • Complete Inhibition of Food-Stimulated Gastric Acid Secretion by Combined Application of Pirenzepine and Ranitidine*
    Gut: first published as 10.1136/gut.22.7.542 on 1 July 1981. Downloaded from Gut, 1981, 22, 542-548 Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine* W LONDONG,t V LONDONG, C RUTHE, AND P WEIZERT From the Medizinische Klinik Innenstadt, University ofMunich, Munich, W Germany SUMMARY In a double-blind, placebo controlled and randomised secretory study the effectiveness of pirenzepine, ranitidine, and their combination was compared intraindividually in eight healthy subjects receiving intravenous bolus injections. Pirenzepine (0.15 mg/kg) plus ranitidine (0-6 mg/kg) suppressed peptone-stimulated gastric acid secretion from 69±11 to 2±0-4 mmol H+/3 h; the mean percentage inhibition was 97%. Postprandial gastrin was unaffected. There were only minor side-effects in a few experiments (reduction of salivation, brief blurring of vision), but no prolactin stimulation after ranitidine or ranitidine plus pirenzepine. The combined application of ranitidine and pirenzepine inhibited meal-stimulated acid secretion more effectively and produced fewer side-effects than the combination of cimetidine plus pirenzepine studied previously. The combined application ofclassical anticholinergics Methods and H2-receptor antagonists inhibits basal and http://gut.bmj.com/ stimulated gastric acid secretion in man more than Each subject had four tests which had to be carried either drug alone.' In double-blind, placebo con- out within a fortnight; the interval between two tests trolled and randomised investigations we have was at least three days. On separate days each subject demonstrated79 that combined intravenous bolus received pirenzepine, ranitidine, pirenzepine plus injections ofthe antimuscarinic drug pirenzepine with ranitidine, and placebo in random order by slow cimetidine suppressed peptone-stimulated acid out- intravenous bolus on a double-blind basis according put more effectively (on average by 90%) than either to a predetermined randomisation code.
    [Show full text]
  • [2-(Diethylamino)Ethyl] Amino-5,11-Dihydro[1]
    Centrally Mediated Inhibitory Effect of 5-[2-(Diethylamino)ethyl] amino-5,11-dihydro[1]benzoxepino[3,4-b]pyridine Trihydrochloride (KW-5805) on Gastric Acid Secretion in Rats ShingoYANO, Yuka KIMURA, Syunji HORIE, Keiichi [TO, NaohiroYAMADA, Makoto MIZUNO and KazuoWATANABE Laboratoryof Chemical Pharmacology, Department of DrugEvaluation and ToxicologicalSciences, Faculty of PharmaceuticalSciences, Chiba University, 1-33 Yayoi-cho, Chiba 260, Japan AcceptedOctober 18, 1989 Abstract-KVV-5805, 5-[2-(diethylamino)ethyl]amino-5,11-dihydro[1 ]benzoxepi no[3,4-b]pyridine trihydrochloride, is a new tricyclic compound with antiulcer activities. Its effect on stimulated gastric acid secretion was investigated in the perfused stomach of anesthetized rats. KW-5805 at 0.3-10 mg/kg, i.v., dose dependently inhibited gastric acid secretion stimulated by 2-deoxy-D-glucose (2 DG). On the other hand, the compound at 10-20 mg/kg, i.v., exerted a moderate decrease in gastric acid secretion stimulated by bethanechol; and at 10 mg/kg, i.v., it produced no change in gastric acid secretion evoked peripherally by vagal electrical stimulation. When applied intracerebroventricularly at 1-5 ,cg/rat, this compound dose-relatedly reduced gastric acid secretion stimulated by 2-DG. Three main metabolites (KF-10504, KF-9530 and KF-10847) of KW-5805 at 1 mg/kg, i.v., caused no significant decrease in gastric acid secretion stimulated by 2-DG. Doxepin, a tricyclic compound, definitely depressed the 2-DG stimulated gastric acid secretion at 1 mg/kg, i.v. It is suggested that intravenous administration of KW-5805 inhibits gastric acid secretion stimulated by 2-DG, mainly via centrally mediated mechanisms, and that biotransformation of KW-5805 to the metabolites contributes little to the development of the antisecretory effect.
    [Show full text]